Clinical Trials

Colonic Neoplasms

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

42 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT01025089 2026-01-07

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

18 enrolled

Thoracic

Thymoma

NCT03290937 2026-01-06

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1 Completed

34 enrolled

Colorectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Phase 2 Active not recruiting

Colorectal Cancer Metastatic

NCT06578559 2026-01-05

BRICKET

16 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

46 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Phase 2 Active not recruiting

Colorectal Cancer Metastatic

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

128 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05959356 2025-12-17

CEIL

198 enrolled

Colorectal Neoplasms

NCT06447987 2025-12-17

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

24 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05956821 2025-12-08

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase 1/2 Recruiting

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

36 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

40 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT00957411 2025-11-24

CETUXICOL

Phase 2 Completed

76 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05200442 2025-11-05

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

53 enrolled

Colorectal Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

43 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Phase 1/2 Recruiting

40 enrolled

CRC

NCT00875849 2025-09-30

AACER

Phase 2 Completed

53 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT01326468 2025-09-25

Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer

Phase NA Withdrawn

Head and Neck Neoplasms

NCT04722523 2025-09-23

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

44 enrolled